Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Roche Gains FDA Approval for Blockbuster MS Drug

By Ryan Bushey | March 29, 2017

Patients diagnosed with multiple sclerosis will soon be able to access a new treatment option.

The Food and Drug Administration (FDA) on Tuesday granted approval to Roche’s MS therapy Ocrevus after a three month delay due to manufacturing issues.

Ocrevus was given the greenlight to treat relapse-remitting MS (RRMS) or primary progressive MS (PPMS), which is the rarer form of the neurological disease.

The agency made the decision after reviewing data from three phase 3 studies showing that Ocrevus was able to significantly slow disability progression and reduce disease activity in the brain better than placebo for PPMS patients while it also was able to suppress disease activity in the brain and reduce relapse rates by nearly half in patients with RRMS better than a rival product from Merck called Rebif.

“The FDA’s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific advance with this first-in-class B-cell targeted therapy”, said Roche’s Chief Medical Officer and Head of Global Product Development Sandra Horning, MD, in a statement.

“Until now, no FDA-approved treatment has been available to the primary progressive MS community, and some people with relapsing forms of MS continue to experience disease activity and disability progression despite available therapies. We believe OCREVUS, given every six months, has the potential to change the disease course for people with MS, and we are committed to helping those who can benefit gain access to our medicine,” continued Horning.

Ocrevus has the potential to be a formidable blockbuster drug because it is the first U.S. approved medicine for treating PPMS. It could generate $3.2 billion in sales for Roche becoming the primary force responsible for the company’s growth over the next few years, according to a report from business intelligence provider GBI Research.

The drug will have an annual list price of $65,000, reported FiercePharma.


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50